Circulating Angiopoietin-2 levels predict mortality in kidney transplant recipients: A 4-year prospective case-cohort study

Transplant International

Volumn 27, Issue 6, 2014, Pages 541-552

  Molnar, Miklos Z ^a,b   Kümpers, Philipp ^c   Kielstein, Jan T ^d   Schiffer, Mario ^d   Czira, Maria E ^e   Ujszaszi, Akos ^e   Kovesdy, Csaba P ^f,g   Mucsi, Istvan ^e,h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

circulating Angiopoietin 2 level; endothelial dysfunction; kidney transplantation; mortality

Indexed keywords

ANGIOPOIETIN 2; HEMOGLOBIN; N(G),N(G) DIMETHYLARGININE; SERUM ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; AGED; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; GRAFT REJECTION; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PREDICTIVE VALUE; PREOPERATIVE CARE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GRAFT REJECTION; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84901227961     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12293     Document Type: Article

References (69)

1. Wolfe RA, Ashby VB, Milford EL, et al,. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
2. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ,. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9: 2135.
3. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K,. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339.
4. Ojo AO, Port FK, Wolfe RA, Mauger EA, Williams L, Berling DP,. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994; 24: 59.
5. Renal transplantation: access and outcomes. United States Renal Data System. Am J Kidney Dis 1998; 32: S89.
6. Herzog CA, Ma JZ, Collins AJ,. Long-term survival of renal transplant recipients in the United States after acute myocardial infarction. Am J Kidney Dis 2000; 36: 145.
7. Howard RJ, Patton PR, Reed AI, et al,. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923.
8. Lentine KL, Brennan DC, Schnitzler MA,. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16: 496.
9. Briggs JD,. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16: 1545.
10. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK,. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
11. Gill JS, Abichandani R, Kausz AT, Pereira BJ,. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int 2002; 62: 1875.
12. Laures AS, Gomez E, Baltar J, Alvarez-Grande J,. Risk factors for cardiovascular disease during the first 2 years after renal transplantation. Transplant Proc 2005; 37: 3778.
13. Chuang P, Gibney EM, Chan L, Ho PM, Parikh CR,. Predictors of cardiovascular events and associated mortality within two years of kidney transplantation. Transplant Proc 2004; 36: 1387.
14. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG,. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000; 57: 1100.
15. Abedini S, Meinitzer A, Holme I, et al,. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010; 77: 44.
16. Davis S, Aldrich TH, Jones PF, et al,. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161.
17. Maisonpierre PC, Suri C, Jones PF, et al,. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55.
18. Suri C, Jones PF, Patan S, et al,. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171.
19. Chang FC, Lai TS, Chiang CK, et al,. Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease. PLoS ONE 2013; 8: e54668.
20. Shroff RC, Price KL, Kolatsi-Joannou M, et al,. Circulating angiopoietin-2 is a marker for early cardiovascular disease in children on chronic dialysis. PLoS ONE 2013; 8: e56273.
21. Brindle NP, Saharinen P, Alitalo K,. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 2006; 98: 1014.
22. Fiedler U, Augustin HG,. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552.
23. Moss A,. The angiopoietin:Tie 2 interaction: a potential target for future therapies in human vascular disease. Cytokine Growth Factor Rev 2013; 24: 579.
24. Kontos CD, Cha EH, York JD, Peters KG,. The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol Cell Biol 2002; 22: 1704.
25. Hughes DP, Marron MB, Brindle NP,. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2. Circ Res 2003; 92: 630.
26. Shantsila E, Lip GY,. Angiopoietins in arterial hypertension: a mechanism of adaptation or a target for treatment? J Hypertens 2009; 27: 1524.
27. Augustin HG, Koh GY, Thurston G, Alitalo K,. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165.
28. Thurston G, Daly C,. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect Med 2012; 2: a006550.
29. Fiedler U, Scharpfenecker M, Koidl S, et al,. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103: 4150.
30. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S,. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002; 99: 1646.
31. Fiedler U, Reiss Y, Scharpfenecker M, et al,. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235.
32. Lim HS, Lip GY, Blann AD,. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005; 180: 113.
33. Nykanen AI, Krebs R, Saaristo A, et al,. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003; 107: 1308.
34. Lee KW, Lip GY, Blann AD,. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110: 2355.
35. Kumpers P, David S, Haubitz M, et al,. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 1638.
36. Kumpers P, Lukasz A, David S, et al,. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care 2008; 12: R147.
37. Parikh SM, Mammoto T, Schultz A, et al,. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3: e46.
38. David S, Kumpers P, Lukasz A, Kielstein JT, Haller H, Fliser D,. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/ pravastatin. J Hypertens 2009; 27: 1641.
39. Eleuteri E, Di Stefano A, Tarro Genta F, et al,. Stepwise increase of angiopoietin-2 serum levels is related to haemodynamic and functional impairment in stable chronic heart failure. Eur J Cardiovasc Prev Rehabil 2011; 18: 607.
40. Lukasz A, Beutel G, Kumpers P, et al,. Angiopoietin-2 in adults with congenital heart disease and heart failure. PLoS ONE 2013; 8: e66861.
41. David S, Kumpers P, Lukasz A, et al,. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 2571.
42. David S, Kumpers P, Hellpap J, et al,. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis 2009; 53: 770.
43. David S, John SG, Jefferies HJ, et al,. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant 2012; 27: 1867.
44. Kovesdy CP, Czira ME, Rudas A, et al,. Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 2010; 10: 2644.
45. Kovesdy CP, Molnar MZ, Czira ME, et al,. Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5: 2297.
46. Molnar MZ, Czira ME, Rudas A, et al,. Association between the malnutrition-inflammation score and post-transplant anaemia. Nephrol Dial Transplant 2011; 26: 2000.
47. Molnar MZ, Keszei A, Czira ME, et al,. Evaluation of the malnutrition-inflammation score in kidney transplant recipients. Am J Kidney Dis 2010; 56: 102.
48. Molnar MZ, Czira ME, Rudas A, et al,. Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients. Am J Kidney Dis 2011; 58: 101.
49. Jassal SV, Schaubel DE, Fenton SS,. Baseline comorbidity in kidney transplant recipients: a comparison of comorbidity indices. Am J Kidney Dis 2005; 46: 136.
50. Levey AS, Stevens LA, Schmid CH, et al,. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
51. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373.
52. Yarlagadda SG, Coca SG, Garg AX, et al,. Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant 2008; 23: 2995.
53. Lukasz A, Hellpap J, Horn R, et al,. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Crit Care 2008; 12: R94.
54. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc 1999; 94: 496.
55. Post S, Peeters W, Busser E, et al,. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 2008; 45: 244.
56. Benedetta Donati M, Gozdzikiewicz J,. Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman. Thromb Haemost 2008; 99: 647.
57. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG,. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005; 118: 771.
58. Lee S, Kim W, Moon SO, et al,. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol Dial Transplant 2007; 22: 396.
59. Lee JS, Song SH, Kim JM, et al,. Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor. Cardiovasc Res 2008; 78: 572.
60. van Meurs M, Kumpers P, Ligtenberg JJ, Meertens JH, Molema G, Zijlstra JG,. Bench-to-bedside review: Angiopoietin signalling in critical illness-a future target? Crit Care 2009; 13: 207.
61. Lim HS, Blann AD, Chong AY, Freestone B, Lip GY,. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004; 27: 2918.
62. Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY,. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 2008; 40: 215.
63. Molnar MZ, Czira M, Ambrus C, et al,. Anemia is associated with mortality in kidney-transplanted patients-a prospective cohort study. Am J Transplant 2007; 7: 818.
64. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M,. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc 2008; 40: 3466.
65. Ong T, McClintock DE, Kallet RH, Ware LB, Matthay MA, Liu KD,. Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit Care Med 2010; 38: 1845.
66. Ricciuto DR, dos Santos CC, Hawkes M, et al,. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011; 39: 702.
67. Golledge J, Clancy P, Yeap BB, Hankey GJ, Norman PE,. Increased serum angiopoietin-2 is associated with abdominal aortic aneurysm prevalence and cardiovascular mortality in older men. Int J Cardiol 2013; 167: 1159.
68. Lorbeer R, Baumeister SE, Dorr M, et al,. Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population. Eur J Heart Fail 2013; 15: 1327.
69. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH,. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6: 283.